Sainatham Chiranjeevi, Yadav Devvrat, Dilli Babu Aravind, Tallapalli Jayanth Reddy, Kanagala Sai Gautham, Filippov Evgenii, Murillo Chavez Franco, Ahmed Nausheen, Lutfi Forat
Department of Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD, United States.
Division of Infectious Diseases, Department of Internal Medicine, University of South Florida, Tampa, FL, United States.
Front Med (Lausanne). 2024 Dec 4;11:1462307. doi: 10.3389/fmed.2024.1462307. eCollection 2024.
Immune cell effector therapies, including chimeric antigen receptor (CAR)-T cells, T-cell receptor (TCR) T cells, natural killer (NK) cells, and macrophage-based therapies, represent a transformative approach to cancer treatment, harnessing the immune system to target and eradicate malignant cells. CAR-T cell therapy, the most established among these, involves engineering T cells to express CARs specific to cancer cell antigens, showing remarkable efficacy in hematologic malignancies like leukemias, B-cell lymphomas, and multiple myeloma. Similarly, TCR-modified therapies, which reprogram T cells to recognize intracellular tumor antigens presented by major histocompatibility complex (MHC) molecules, offer promise for a range of solid tumors. NK-cell therapies leverage NK cells' innate cytotoxicity, providing an allogeneic approach that avoids some of the immune-related complications associated with T-cell-based therapies. Macrophage-based therapies, still in early stages of the development, focus on reprogramming macrophages to stimulate an immune response against cancer cells in the tumor microenvironment. Despite their promise, socioeconomic and regulatory challenges hinder the accessibility and scalability of immune cell effector therapies. These treatments are costly, with CAR-T therapies currently exceeding $400,000 per patient, creating significant disparities in access based on socioeconomic status and geographic location. The high manufacturing costs stem from the personalized, labor-intensive processes of harvesting, modifying, and expanding patients' cells. Moreover, complex logistics for manufacturing and delivering these therapies limit their reach, particularly in low-resource settings. Regulatory pathways further complicate the landscape. In the United States., the Food and Drug Administrations' (FDA) accelerated approval processes for cell-based therapies facilitate innovation but do not address cost-related barriers. In Europe, the European Medicines Agency (EMA) offers adaptive pathways, yet decentralized reimbursement systems create uneven access across member states. Additionally, differing regulatory standards for manufacturing and quality control worldwide pose hurdles for global harmonization and access. To expand the reach of immune effector cell therapies, a multipronged approach is needed-streamlined regulatory frameworks, policies to reduce treatment costs, and international collaborations to standardize manufacturing. Addressing these socioeconomic and regulatory obstacles is essential to make these life-saving therapies accessible to a broader patient population worldwide. We present a literature review on the current landscape of immune effector cell therapies and barriers of access to currently approved standard of care therapy at various levels.
免疫细胞效应疗法，包括嵌合抗原受体（CAR）-T细胞、T细胞受体（TCR）T细胞、自然杀伤（NK）细胞和基于巨噬细胞的疗法，代表了一种变革性的癌症治疗方法，即利用免疫系统来靶向和根除恶性细胞。CAR-T细胞疗法是这些疗法中最成熟的，它涉及对T细胞进行工程改造，使其表达针对癌细胞抗原的CAR，在白血病、B细胞淋巴瘤和多发性骨髓瘤等血液系统恶性肿瘤中显示出显著疗效。同样，TCR修饰疗法通过重新编程T细胞以识别主要组织相容性复合体（MHC）分子呈递的细胞内肿瘤抗原，为一系列实体瘤带来了希望。NK细胞疗法利用NK细胞的天然细胞毒性，提供了一种异基因方法，避免了一些与基于T细胞的疗法相关的免疫相关并发症。基于巨噬细胞的疗法仍处于开发的早期阶段，重点是对巨噬细胞进行重新编程，以刺激肿瘤微环境中针对癌细胞的免疫反应。尽管它们前景广阔，但社会经济和监管挑战阻碍了免疫细胞效应疗法的可及性和可扩展性。这些治疗成本高昂，目前CAR-T疗法每位患者超过40万美元，基于社会经济地位和地理位置造成了显著的可及性差异。高昂的制造成本源于采集、改造和扩增患者细胞的个性化、劳动密集型过程。此外，制造和交付这些疗法的复杂物流限制了它们的覆盖范围，特别是在资源匮乏的地区。监管途径进一步使情况复杂化。在美国，食品药品监督管理局（FDA）对基于细胞的疗法的加速审批过程促进了创新，但没有解决与成本相关的障碍。在欧洲，欧洲药品管理局（EMA）提供了适应性途径，但分散的报销系统导致各成员国之间的可及性不均衡。此外，全球范围内制造和质量控制的不同监管标准给全球协调和可及性带来了障碍。为了扩大免疫效应细胞疗法的覆盖范围，需要采取多管齐下的方法——简化监管框架、降低治疗成本的政策以及使制造标准化的国际合作。解决这些社会经济和监管障碍对于使这些挽救生命的疗法在全球范围内更广泛的患者群体中可及至关重要。我们对免疫效应细胞疗法的当前格局以及各级获得当前批准的标准治疗的障碍进行了文献综述。
